Immunology

Latest News
September 4th 2025

Methotrexate May Lower Blood Pressure in Rheumatoid Arthritis

August 30th 2025

Smoking Remains a Major Driver of Rheumatoid Arthritis Burden Worldwide

August 28th 2025

Rheumatoid Arthritis Linked to Elevated Risk of Degenerative Valvular Heart Disease

August 28th 2025

Shingles Vaccine Generates Strong Immune Response in Patients With RA Receiving Upadacitinib

August 13th 2025

Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions

Video Interviews
View All
February 26th 2025

Real-World Data and Ongoing Research Into Bimekizumab-bkzx

February 24th 2025

Enhancing Patient Access Through Navigation Assistance

February 19th 2025

How Nipocalimab Targets Unmet Needs in Autoimmune Care

February 10th 2025

Bimekizumab-bkzx Expands Treatment Options for Inflammatory Conditions

October 29th 2024

Long-Term Bimekizumab Data Offer New Hope for HS Management

Podcasts
View All
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

More News

Janet Pope, MD, MPH
August 11th 2025

Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH

Hayden E. Klein Janet Pope, MD, MPH
Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
AJMC
August 1st 2025

US Health Care Disparities in Immunology Biologics Access: A Systematic Review

Grace C. Wright, MD, PhD Ginette A. Okoye, MD Adam C. Ehrlich, MD, MPH D. J. Lorimier, PharmD, MS Shahnaz Khan, MPH Alisha Krumbach, PharmD Catherine Copley-Merriman, MS, MBA Kateryna Onishchenko, PhD Osayi Ovbiosa, PhD Manish Mittal, PhD
This article presents a systematic review of US health care disparities in biologics access across immunology (ie, rheumatology, dermatology, and gastroenterology) and a call to action.
Juvenile arthritis awareness month | Image credit: Ocha Designs – stock.adobe.com
Published: July 29th 2025 | Updated: July 29th 2025

Adalimumab, Etanercept Biosimilars Deliver Real-World Results for Juvenile Idiopathic Arthritis

Hayden E. Klein
Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts.
little girl who likes cow's milk | Image credit: Irina Schmidt - stock.adobe.com
July 16th 2025

Cow’s Milk Allergy in Breastfed Infants: What Clinicians and Families Need to Know

Skylar Jeremias
A new review explores the complexities of cow's milk allergy in breastfed infants, including symptoms, diagnosis challenges, and the impact of maternal diet.
Group of doctors talking and looking at tablet | Image credit: Seventyfour – stock.adobe.com
July 9th 2025

Patients With RA and Cancer Seek More Clarity, Collaboration in Treatment Decisions

Hayden E. Klein
Many patients value conversations with their rheumatologists and oncologists more than just reading information from a website.
Older woman eating salad on yoga mat | Image credit: Prostock-studio – stock.adobe.com
July 3rd 2025

Plant-Based Diet May Improve Stress-Related Metrics in Rheumatoid Arthritis

Hayden E. Klein
The lifestyle intervention included a whole-food plant-based diet, exercise, sleep, and stress management components.
Dentist consulting patient | Image credit: D Theron/peopleimages.com – stock.adobe.com
June 30th 2025

Dental Infections Pose Risks for Hospitalized Patients With Rheumatoid Arthritis

Hayden E. Klein
High infection rates among younger adults suggest they either delay routine dental care and only seek treatment when conditions become severe, or face more barriers.
Doctor explaining notes to patient | Image credit: Minerva Studio – stock.adobe.com
June 30th 2025

Patient Materials for Rheumatoid Arthritis Often Miss Crucial Information

Hayden E. Klein
Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and improve shared decision-making.
Stressed older woman | Image credit: InsideCreativeHouse – stock.adobe.com
June 24th 2025

Musculoskeletal Disorders in Postmenopausal Women Are Rising Worldwide

Hayden E. Klein
Osteoarthritis leads the burden, projected to affect 50% of postmenopausal women by 2045.
FDA building sign | Image credit: Tada Images – stock.adobe.com
June 24th 2025

FDA Approves At-Home Belimumab Autoinjector for Pediatric Lupus Nephritis

Hayden E. Klein
Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.
Rheumatoid arthritis in hand | Image credit: yodiyim – stock.adobe.com
June 12th 2025

Subcutaneous Tocilizumab Superior to Methotrexate in Chinese Patients With RA

Hayden E. Klein
Tocilizumab alone and in combination with methotrexate outperformed the latter drug in patients who did not adequately respond to conventional synthetic disease-modifying antirheumatic drugs.
AChR-Ab titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. | Image credit: luchschenF - stock.adobe.com
February 21st 2025

AChR-Ab Titers Associated With Myasthenia Gravis Severity

Rose McNulty
Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.
Hidradenitis suppurativa. | Image Credit: MdBabul - stock.adobe.com
February 13th 2025

Bimekizumab for Hidradenitis Suppurativa Offers Durable Disease Control in Long-Term Data

Cameron Santoro
New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable treatment option for patients.
Myasthenia gravis | Image Credit: © Yurii Kibalnik-stock.adobe.com
February 7th 2025

Phase 3 Data Support Nipocalimab for Myasthenia Gravis

Maggie L. Shaw
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and efficacy of nipocalimab for myasthenia gravis.
Jeff Stark, MD, UCB
February 6th 2025

Dr Jeff Stark: New Bimzelx Dose Offers Simplicity and Choice

Maggie L. Shaw Jeff Stark, MD
On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.
Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine
January 29th 2025

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

Maggie L. Shaw Katie Abouzahr, MD
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Hidradenitis Suppurativa | Image Credit: © Yurii Kibalnik-stock.adobe.com
January 26th 2025

Hidradenitis Suppurativa, Porokeratosis Overlap in Rare Case Study

Emma Andrus
This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique histopathology and complications
Christopher Sayed, MD
January 22nd 2025

Hidradenitis Suppurativa Onset and Treatment: Challenges and Hope for Patients

Maggie L. Shaw Christopher Sayed, MD
Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.
Katie Abouzahr, MD, Johnson & Johnson
January 17th 2025

Understanding gMG: Autoantibodies and Life-Altering Muscle Weakness

Maggie L. Shaw
Generalized myasthenia gravis (gMG) is an autoantibody-driven chronic disease for which there is no cure.
Psoriatic arthritis | Image Credit: © Andrii-stock.adobe.com
January 15th 2025

Pain, Fatigue With Bimekizumab for PsA Tied to Swollen Joints

Maggie L. Shaw
Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on data from 2 phase 3 trials: BE OPTIMAL and BE COMPLETE.
hidradenitis suppurativa | Image Credit: © syahrir-stock.adobe.com
January 8th 2025

C-Reactive Protein May Guide HS Treatment Choices

Maggie L. Shaw
With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set out to evaluate the potential of biomarkers to estimate potential treatment response.
Chris Sayed, MD
January 3rd 2025

HS Treatment Goals: Better Quality of Life, Not Just Control

Maggie L. Shaw
For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurativa (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
SPD Highlights thumbnail
December 30th 2024

ICYMI: Highlights From SPD 2024

Maggie L. Shaw
The Society for Pediatric Dermatology (SPD) Annual Meeting took place in Toronto, Canada, July 11-15, with our top coverage including the hot topics of combating misinformation and improving care for children with dermatologic conditions.
AAD 2024 highlights thumbnail
December 22nd 2024

ICYMI: Highlights From AAD 2024

Maggie L. Shaw
The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to 11.
Top 5 Most-Read Immunology Articles of 2024
December 18th 2024

Top 5 Most-Read Immunology Articles of 2024

Maggie L. Shaw
Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, highlighting studies on gut bacteria, radiographic progression, socioeconomic factors, and bimekizumab's persistent efficacy across multiple disease states.
Christopher Sayed, MD, UNC School of Medicine
December 12th 2024

Subcutaneous HS Therapy: Efficacy and Safety Insights

Maggie L. Shaw
In the continuation of our discussion with Chris Sayed, MD, University of North Carolina at Chapel Hill Department of Dermatology, he discusses the benefits of subcutaneous treatment of hidradenitis suppurativa, the chronic inflammatory skin condition.
Asembia Top 5 Thumbnail
December 3rd 2024

ICYMI: Highlights From Asembia 2024

Maggie L. Shaw
Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients front and center.
Christopher Sayed, MD, UNC Chapel Hill
November 26th 2024

BE HEARD Trials Highlight Efficacy of Bimekizumab in Hidradenitis Suppurativa

Maggie L. Shaw
On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.
FDA | Image Credit: © Deni-stock.adobe.com
November 20th 2024

FDA Approves Bimekizumab in Hidradenitis Suppurativa

Maggie L. Shaw
This approval is the fifth overall for bimekizumab (Bimzelx; UCB Pharma) in the US, and they all have come in the last 13 months.
Psoriatic arthritis | Image Credit: © MQ-Illustrations-stock.adobe.com
November 19th 2024

New PsA Data Highlight Long-Term Benefits of Bimekizumab

Maggie L. Shaw
A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
1234>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo